miR-381-3p suppresses breast cancer progression by inhibition of epithelial–mesenchymal transition

Yu, Yong-Zheng; Mu, Qiang; Ren, Qian; Xie, Lei; Wang, Qitang; Wang, Cuiping

doi:10.1186/s12957-021-02344-w

Cited by 17 publications

(12 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we hypothesized that miR-381-3p may become a clinical diagnostic and therapeutic target of UF. Definitely, due to spatial heterogeneity in tumor tissue, miR-381-3p was regarded as a tumor suppressor in gastric cancer ( Gao et al, 2022 ), breast cancer ( Yu et al, 2021 ) and bladder cancer ( Li et al, 2019 ). We performed in vitro experiments to examine the function of miR-381-3p on UF, and the results verified our hypothesis.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of miRNA-TF-mRNA Regulatory Networks in Uterine Fibroids

Peng

Liu

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Uterine fibroids (UF) are the most common benign gynecologic tumors and lead to heavy menstrual bleeding, severe anemia, abdominal pain, and infertility, which seriously harm a women’s health. Unfortunately, the regulatory mechanisms of UF have not been elucidated. Recent studies have demonstrated that miRNAs play a vital role in the development of uterine fibroids. As a high-throughput technology, microarray is utilized to identify differentially expressed genes (DEGs) and miRNAs (DEMs) between UF and myometrium. We identified 373 candidate DEGs and the top 100 DEMs. Function enrichment analysis showed that candidate DEGs were mainly enriched in biological adhesion, locomotion and cell migration, and collagen-containing extracellular matrix. Subsequently, protein-protein interaction (PPI) networks are constructed to analyze the functional interaction between DEGs and screen hub DEGs. Subsequently, the expression levels of hub DEGs were validated by real-time PCR of clinical UF samples. The DGIdb database was used to select candidate drugs for hub DEGs. Molecular docking was applied to test the affinity between proteins and drugs. Furthermore, target genes for 100 candidate DEMs were predicted by miRwalk3.0. After overlapping with 373 candidate DEGs, 28 differentially expressed target genes (DEGTs) were obtained. A miRNA-mRNA network was constructed to investigate the interactions between miRNA and mRNA. Additionally, two miRNAs (hsa-miR-381-3p and hsa-miR-181b-5p) were identified as hub DEMs and validated through RT-PCR. In order to better elucidate the pathogenesis of UF and the synergistic effect between miRNA and transcription factor (TF), we constructed a miRNA-TF-mRNA regulatory network. Meanwhile, in vitro results suggested that dysregulated hub DEMs were associated with the proliferation, migration, and apoptosis of UF cells. Our findings provided a novel horizon to reveal the internal mechanism and novel targets for the diagnosis and treatment of UF.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification and Validation of miRNA-TF-mRNA Regulatory Networks in Uterine Fibroids

Peng

Liu

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Herein, we investigated the role and possible mechanism of miR-381-3p in glioma. miR-381-3p is abnormally expressed in multiple cancers [ 12 , 14 , 15 ] and is widely described as a tumor suppressor gene, which can modulate proliferation, migration, and invasion potential of cancer cells and stimulate apoptosis. We explored miR-381-3p expression via bioinformatics analysis and qRT-PCR and noted miR-381-3p downregulation in glioma.…”

Section: Discussionmentioning

confidence: 99%

miR-381-3p Involves in Glioma Progression by Suppressing Tumor-Promoter Factor ANTXR1

Dong

Zhang

Niu

et al. 2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Accumulating studies revealed association between development of glioma and miRNA dysregulation. A case in point is miR-381-3p, but its mechanism in glioma is unclear yet. In this work, we confirmed that overexpressed miR-381-3p repressed biological functions of glioma cells. Additionally, we also discovered that upregulated anthrax toxin receptor 1 (ANTXR1) was negatively mediated by miR-381-3p. We further proved that miR-381-3p-targeted ANTXR1 was able to counteract the suppression of miR-381-3p on biological functions of glioma. We concluded that miR-381-3p and ANTXR1 were both important factors in modulating glioma progression. miR-381-3p/ANTXR1 axis is expected to be a molecular target for glioma.

show abstract

“…Therefore, with the development of bioinformatics, an increasing number of novel biomarkers have been constructed to get involved in the diagnosis and prediction of cancer [ 28 , 29 ]. These signatures are associated with metabolism [ 30 ], immune [ 31 ], and DNA methylation [ 32 ]. The standards to judge the model are convenient, credible, and precise.…”

Section: Discussionmentioning

confidence: 99%

Identification of a novel glycolysis-related signature to predict the prognosis of patients with breast cancer

Deng

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

Background Breast cancer (BC) has a high incidence and mortality rate in females. Its conventional clinical characteristics are far from accurate for the prediction of individual outcomes. Therefore, we aimed to develop a novel signature to predict the survival of patients with BC. Methods We analyzed the data of a training cohort from the Cancer Genome Atlas (TCGA) database and a validation cohort from the Gene Expression Omnibus (GEO) database. After the applications of Gene Set Enrichment Analysis (GSEA) and Cox regression analyses, a glycolysis-related signature for predicting the survival of patients with BC was developed; the signature contained AK3, CACNA1H, IL13RA1, NUP43, PGK1, and SDC1. Furthermore, on the basis of expression levels of the six-gene signature, we constructed a risk score formula to classify the patients into high- and low-risk groups. The receiver operating characteristic (ROC) curve and the Kaplan-Meier curve were used to assess the predicted capacity of the model. Later, a nomogram was developed to predict the outcomes of patients with risk score and clinical features over a period of 1, 3, and 5 years. We further used Human Protein Atlas (HPA) database to validate the expressions of the six biomarkers in tumor and sample tissues, which were taken as control. Results We constructed a six-gene signature to predict the outcomes of patients with BC. The patients in the high-risk group showed poor prognosis than those in the low-risk group. The area under the curve (AUC) values were 0.719 and 0.702, showing that the prediction performance of the signature is acceptable. Additionally, Cox regression analysis revealed that these biomarkers could independently predict the prognosis of BC patients with BC without being affected by clinical factors. The expression levels of all six biomarkers in BC tissues were higher than that in normal tissues; however, AK3 was an exception. Conclusion We developed a six-gene signature to predict the prognosis of patients with BC. Our signature has been proved to have the ability to make an accurate prediction and might be useful in expanding the hypothesis in clinical research.

show abstract

miR-381-3p suppresses breast cancer progression by inhibition of epithelial–mesenchymal transition

Cited by 17 publications

References 45 publications

Identification and Validation of miRNA-TF-mRNA Regulatory Networks in Uterine Fibroids

Identification and Validation of miRNA-TF-mRNA Regulatory Networks in Uterine Fibroids

miR-381-3p Involves in Glioma Progression by Suppressing Tumor-Promoter Factor ANTXR1

Identification of a novel glycolysis-related signature to predict the prognosis of patients with breast cancer

Contact Info

Product

Resources

About